Emzumab — Omalizumab
Omalizumab takes a different immunological target than most of our biologics catalogue — instead of TNF or checkpoint pathways, it neutralizes IgE, the antibody at the center of allergic reactions, making it the go-to biologic for allergic disease that hasn't responded to standard inhaled or oral therapy. Export demand for this product has been rising steadily alongside increasing asthma diagnosis rates in rapidly urbanizing markets across Africa and Southeast Asia, where environmental allergen exposure and diagnostic capacity are both expanding.
- Approved indications: Moderate-to-severe persistent allergic asthma uncontrolled by standard therapy, chronic rhinosinusitis with nasal polyps, chronic spontaneous urticaria
- Mechanism: Binds free IgE antibodies, preventing them from triggering the allergic cascade responsible for asthma symptoms, chronic hives, and related conditions
- Dosing determination: Based on baseline IgE levels and body weight — requires lab testing before dosing can be calculated, a point relevant for distributors confirming buyer diagnostic capability
- Demand driver: Rising urban asthma prevalence across Africa and Southeast Asia is a meaningful contributor to increasing regional export enquiries
Key Product Facts
150 mg
Strength
1 Vial
Pack Size
Omalizumab
Active Ingredient
Immunology
Category
Enquire Now for Pricing
Price
Omalizumab takes a different immunological target than most of our biologics catalogue — instead of TNF or checkpoint pathways, it neutralizes IgE, the antibody at the center of allergic reactions, making it the go-to biologic for allergic disease that hasn't responded to standard inhaled or oral therapy. Export demand for this product has been rising steadily alongside increasing asthma diagnosis rates in rapidly urbanizing markets across Africa and Southeast Asia, where environmental allergen exposure and diagnostic capacity are both expanding.
- Approved indications: Moderate-to-severe persistent allergic asthma uncontrolled by standard therapy, chronic rhinosinusitis with nasal polyps, chronic spontaneous urticaria
- Mechanism: Binds free IgE antibodies, preventing them from triggering the allergic cascade responsible for asthma symptoms, chronic hives, and related conditions
- Dosing determination: Based on baseline IgE levels and body weight — requires lab testing before dosing can be calculated, a point relevant for distributors confirming buyer diagnostic capability
- Demand driver: Rising urban asthma prevalence across Africa and Southeast Asia is a meaningful contributor to increasing regional export enquiries
- Latex caution: The syringe cap on some presentations contains latex — must be flagged for patients with known latex allergy
- Caution populations: Renal or hepatic disease, pre-existing autoimmune conditions
- Pediatric use: Safety and effectiveness not established in young children — confirm age-appropriate indication before ordering
- Anaphylaxis risk: Rare but documented, typically within hours of the first few doses — monitoring recommended
| Document |
Included |
| Certificate of Analysis (COA) |
Standard |
| Certificate of Origin (COO) |
Standard |
| MSDS |
Standard |
Stock status: In stock for export | Quote turnaround: 24 hours
- Logistics: GDP-compliant cold-chain export (2–8°C)
- Coverage: Global, with growing demand specifically from Africa and Southeast Asia
- Tracking: Full shipment tracking included
What is Omalizumab used for?
Treats moderate-to-severe allergic asthma, chronic urticaria, and nasal polyps that haven't responded to standard treatment.
Get Omalizumab price from a GMP-compliant Indian supplier — how?
Send strength and destination for a verified quote.
Is it safe with a latex allergy?
Caution is needed — the syringe cap on some presentations may contain latex.
How is the dose determined?
Based on the patient's baseline IgE level and body weight, requiring lab testing beforehand.
Who supplies Omalizumab from India?
WHO-GMP certified manufacturer with full export documentation.
